Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efineptakin alfa + ciltacabtagene autoleucel
- Development stage
- Unknown
- Lead developer
- NeoImmuneTech
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Intravenous
01
Overview
efineptakin alfa + ciltacabtagene autoleucel is a combination immunotherapy being investigated for the treatment of relapsed or refractory multiple myeloma. The regimen consists of **NT-I7** (efineptakin alfa), a long-acting recombinant human interleukin-7 (IL-7) fused to a hybrid Fc region (hyFc), and **ciltacabtagene autoleucel** (Carvykti), an autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA). NT-I7 acts as an IL-7 receptor agonist designed to promote the expansion, survival, and metabolic fitness of T cells, including the engineered CAR-T cells, to improve the durability of clinical responses. This specific combination is currently being evaluated in a Phase Ib clinical trial led by the **Washington University School of Medicine** to assess safety and the potential to enhance the efficacy of standard BCMA-targeted CAR-T therapy in patients with multiple myeloma.
- Brand names
- Carvykti
- Other names
- rhIL-7-hyFcrhIL7-hyFcrhIL 7-hyFccilta-celrecombinant human interleukin-7B-cell Maturation Antigen (BCMA) CART-T therapy
02
Targets
IL7R (Interleukin-7 Receptor)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on efineptakin alfa + ciltacabtagene autoleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efineptakin alfa + ciltacabtagene autoleucel.